GlassScriptPhysician profile
Dustin B Feldman
NPI 1689894867
$10,759.57
in general payments reported to CMS, 2019-2025
45 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,414 · 2020: $714 · 2021: $1,267 · 2022: $1,534 · 2023: $1,274 · 2024: $2,482 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,813 · Consulting Fee: $15.79 · Travel and Lodging: $2.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,813.02 |
| Consulting Fee | $15.79 |
| Travel and Lodging | $2.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,915.68 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Tacticath Ablation Catheter, Sensor Enabled |
| Novartis Pharmaceuticals Corporation | $1,126.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $837.34 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $780.43 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $705.86 | 2019-2025 | Lifevest |
| Amgen INC. | $646.97 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $590.56 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $496.69 | 2019-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $422.37 | 2023-2025 | Onpattro, Amvuttra |
| Medtronic, INC. | $374.02 | 2022-2025 | Cardioblate Gemini, Symplicity G3 |
| Pfizer INC. | $368.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $355.39 | 2019-2025 | Wainua, Brilinta |
| Esperion Therapeutics, INC. | $279.63 | 2021-2025 | Nexletol |
| Inari Medical, INC. | $159.70 | 2022 | |
| Novo Nordisk INC | $150.18 | 2024-2025 | Wegovy, Ozempic |
Show all 43 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.